|1.||Ferrone, Soldano: 4 articles (06/2012 - 12/2005)|
|2.||Rokeach, Luis A: 2 articles (01/2015 - 01/2009)|
|3.||Wang, Xinhui: 2 articles (06/2012 - 06/2007)|
|4.||Michalak, Marek: 2 articles (11/2011 - 01/2004)|
|5.||Wang, Bei: 2 articles (09/2009 - 02/2008)|
|6.||Han, Shuhong: 2 articles (09/2009 - 02/2008)|
|7.||Chang, Lung-Ji: 2 articles (09/2009 - 02/2008)|
|8.||Krishnakumar, Subramanian: 2 articles (03/2004 - 12/2003)|
|9.||Abhyankar, Dhiraj: 2 articles (03/2004 - 12/2003)|
|10.||Biswas, Jyotirmay: 2 articles (03/2004 - 12/2003)|
|1.||Prion Diseases (Transmissible Spongiform Encephalopathies)
|2.||Melanoma (Melanoma, Malignant)
01/20/2004 - "Our data suggest that chaperone-downregulation, particularly calnexin-downregulation, may contribute to the metastatic phenotype of melanoma cells in vivo. "
01/20/2004 - "Metastatic melanoma lesions exhibited significant downregulation of calnexin as compared to primary melanoma lesions. "
08/01/1993 - "We have recently identified a gene encoding a calnexin-like protein (p90) by the immunoscreening of a human melanoma cDNA library, using a rabbit anti-human melanosomal antibody. "
01/20/2004 - "Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma."
01/20/2004 - "In the present study, we compared melanoma lesions representing different stages of tumor progression with regard to the expression of calnexin and calreticulin in tumor cells by means of immunohistochemistry. "
06/01/2007 - "LMP2, LMP7, calnexin, beta2-microglobulin-free heavy chain (HC) and beta2-microglobulin were down-regulated or undetectable in Mb lesions, but not in astrocytic tumors or normal fetal cerebellum. "
12/01/2001 - "In particular, calnexin expression was strongly downregulated in 69% of cervical cancer lesions analyzed. "
01/01/2015 - "Finally, HCAb2 specifically targeted calnexin negative xenograft tumor cells. "
11/07/2014 - "Among them, 14-3-3 beta/alpha and calnexin were reported to be potentially involved in tumor recurrence and the malignant properties of lung cancer. "
06/01/2012 - "Taken together, our data suggest that patients with low or defective TAP1 or calnexin in primary breast cancers may be at higher risks for developing brain metastasis due to the defects in T cell-based immunosurveillance."
10/21/1994 - "Biosynthetic labeling was used to study the interactions of two chaperones, BiP and calnexin, with vesicular stomatitis virus (VSV) glycoprotein (G protein). "
01/01/2015 - "Effect of ionomycin on interaction of calnexin with vesicular stomatitis virus glycoprotein is cell type-specific."
03/12/1999 - "To analyze the role of glucose trimming and reglucosylation in the binding of substrate proteins to calnexin in the endoplasmic reticulum (ER) of living cells, we made use of the thermosensitive vesicular stomatitis virus tsO45 glycoprotein (G protein). "
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/12/2013 - "In this study, we first performed double-immunocytochemical staining of Tespa1 with a mitochondrial marker or an ER marker on an acute T lymphoblastic leukemia cell line, Jurkat cells, by using anti-ATP synthase or anti-calnexin antibody, respectively, and demonstrated that Tespa1 was localized very close to mitochondria and the Tespa1 localization was overlapped with restricted portion of ER. "
|3.||GTP-Binding Proteins (G-Protein)
|5.||transporter associated with antigen processing (TAP)
|6.||Ursodeoxycholic Acid (Urso)
|7.||Staphylococcal Protein A (A, Protein)
|8.||Adenosine Triphosphate (ATP)
|10.||Proteins (Proteins, Gene)
|1.||Heterologous Transplantation (Xenotransplantation)